S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

CRDF Cardiff Oncology Inc

3.95

-0.28 (-6.62%)

After Hours

Last Updated: 09:23:03

Delayed by 15 minutes

Cardiff Oncology defended at Baird despite cancer-data led selloff

To read the full story on Seeking Alpha, click here.

Cardiff Oncology (NASDAQ:CRDF)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Cardiff Oncology Charts.

Cardiff Oncology (NASDAQ:CRDF)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Cardiff Oncology Charts.

Cardiff Oncology Inc News

Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update
Friday 3 May 2024 (4 hours ago) • GlobeNewswire Inc.

Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update
Friday 26 April 2024 (1 week ago) • GlobeNewswire Inc.

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
Tuesday 9 April 2024 (3 weeks ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Friday 8 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 8 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 8 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 8 March 2024 (2 months ago) • Edgar (US Regulatory)

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024
Thursday 7 March 2024 (2 months ago) • GlobeNewswire Inc.

Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
Friday 1 March 2024 (2 months ago) • GlobeNewswire Inc.

Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC
Friday 1 March 2024 (2 months ago) • GlobeNewswire Inc.

Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)
Friday 1 March 2024 (2 months ago) • GlobeNewswire Inc.

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Friday 1 March 2024 (2 months ago) • Edgar (US Regulatory)

More Cardiff Oncology Inc News Articles

Sterling vs AUD

Australian SE All Ordina...

JP Morgan Chase

Westpac Banking

Verizon Communications

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions